Schistosomiasis | ||
| Egyptian Pharmaceutical Journal | ||
| Volume 11, Issue 1, June 2012, Pages 1-15 PDF (1.67 M) | ||
| DOI: 10.7123/01.EPJ.0000415037.38143.d4 | ||
| Authors | ||
| Magdy I. El-Zahar; Somaia Abd El-Karim | ||
| Abstract | ||
Schistosomiasis is a chronic parasitic disease affecting about 207 million individuals worldwide. It is still a major health problem in many tropical and subtropical countries, as well as for travelers from developed countries. The treatment strategies of schistosomiasis can be divided into two main routes: (a) chemotherapy treatment including trivalent antimony compounds, hycanthone mesylate, niridazole, metrifonate, oxamniquine, oltipraz, artemisinins, albendazole, amoscanate mirazid, and praziquantel; (b) vaccines that may play an important role in the control of schistosomiasis in the future. | ||
| Keywords | ||
| Chemotherapy; praziquantel; Schistosomiasis; vaccines | ||
|
Statistics Article View: 56 PDF Download: 25 |
||
